Hasil Pencarian - Ikei S. Kobayashi, MD, PhD

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

    Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations oleh Pedro E.N.S. Vasconcelos, MS, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors

    The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors oleh Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

    EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors oleh Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: